Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis

Overview of attention for article published in Clinical Pharmacology : Advances and Applications, February 2016

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#33 of 179)
High Attention Score compared to outputs of the same age (84th percentile)

Mentioned by

blogs: 1 blog

twitter: 3 X users

Citations

dimensions_citation: 14 Dimensions

Readers on

mendeley: 23 Mendeley

Summary Blogs X Dimensions citations

So far, Dimensions has found 14 publications that cite this research output.

14

The most recent citing publications are shown below. View all 14 publications that cite this research output on Dimensions.

Treatment optimization of maintenance immunosuppressive agents in pediatric renal transplant recipients

Article in Expert Opinion on Drug Metabolism & Toxicology (June 2021)

Severe cutaneous adverse event in a daclizumab-treated multiple sclerosis patient

Article in Multiple Sclerosis and Related Disorders (June 2019)

Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis

Article in Biomedicines (March 2019)